Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C [Phase 3]

View source ↗

Summary

Phase 3 study of K-877 (pemafibrate) in Chinese patients with high triglycerides and low HDL-C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• K-877 (pemafibrate) (pemafibrate)

Snippet

Sponsor: Kowa Company, Ltd. | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED